Predictors of residual tumor in breast-conserving therapy
Breast-conserving therapy is considered to be the standard treatment for early breast tumors (T1-T2). In up to 82 % of breast-conserving surgery, tumor cells were still found to be present at or near the cut edge of the surgical specimen after surgery. Thus, it is of clinical need to identify tumors...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 July 2015
|
| In: |
Annals of surgical oncology
Year: 2015, Jahrgang: 22, Heft: 3, Pages: 451-458 |
| ISSN: | 1534-4681 |
| DOI: | 10.1245/s10434-015-4736-4 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1245/s10434-015-4736-4 |
| Verfasserangaben: | Michelle G. Rath, Lorenz Uhlmann, Joerg Heil, Christoph Domschke, Zdravka Roth, Hans-Peter Sinn, Frederik Marme, Alexander Scharf, Andreas Schneeweiss, Meinhard Kieser, Christof Sohn, and Joachim Rom |
| Zusammenfassung: | Breast-conserving therapy is considered to be the standard treatment for early breast tumors (T1-T2). In up to 82 % of breast-conserving surgery, tumor cells were still found to be present at or near the cut edge of the surgical specimen after surgery. Thus, it is of clinical need to identify tumors at high probability for reexcision in the preoperative setting. |
|---|---|
| Beschreibung: | Gesehen am 10.06.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1534-4681 |
| DOI: | 10.1245/s10434-015-4736-4 |